Zanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)

NCT06549335 · clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
66
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Ruijin Hospital